Update on the therapy for myelodysplastic syndrome
- 4 February 2009
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 84 (3), 177-186
- https://doi.org/10.1002/ajh.21352
Abstract
The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders characterized by cytopenias. Patients have a risk of developing acute leukemia though most subcome to complications of low blood counts. Over the past decade many novel treatments have been developed and investigation of new agents is ongoing. In this article, we discuss the classification and prognostic systems that are used in MDS, the agents available for treatment of MDS as well as review supportive and palliative care options for patients who are not candidates for, or opt against, newer treatment strategies. Am. J. Hematol. 2009.Keywords
This publication has 101 references indexed in Scilit:
- Myelodysplastic syndromesBlood, 2008
- DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic SyndromesSeminars in Hematology, 2008
- Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersBlood, 2007
- Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non‐Hodgkin’s lymphoma receiving combination chemotherapyBritish Journal of Haematology, 2007
- A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromesCancer, 2007
- AMG 531 for Chronic ITPNew England Journal of Medicine, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialBlood, 2004
- The WHO classification of MDS does make a differenceBlood, 2004
- The Secondary Leukemias: Challenges and Research DirectionsJNCI Journal of the National Cancer Institute, 1996